NLRP3 and lymphoma: Although, in this study, the effects of BOT-4-one on NLRP3 inflammasome assembly were not investigated, the observed antitumor effect on lymphoma cells could partly be attributed to the compound’s inhibitory properties on NLRP3 inflammasome assembly, rendering it a possible candidate for future clinical investigation.